Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2010 1
2011 1
2012 2
2015 1
2016 1
2017 1
2018 1
2019 2
2020 2
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
Carboxylesterase-1 assisted targeting of HDAC inhibitors to mononuclear myeloid cells in Inflammatory Bowel Disease.
Elfiky AMI, Ghiboub M, Li Yim AYF, Hageman IL, Verhoeff J, de Krijger M, van Hamersveld PHP, Welting O, Admiraal I, Rahman S, Garcia-Vallejo JJ, Wildenberg ME, Tomlinson L, Gregory R, Rioja I, Prinjha RK, Furze RC, Lewis HD, Mander PK, Heinsbroek SEM, Bell MJ, de Jonge WJ. Elfiky AMI, et al. Among authors: de jonge wj. J Crohns Colitis. 2021 Oct 11:jjab176. doi: 10.1093/ecco-jcc/jjab176. Online ahead of print. J Crohns Colitis. 2021. PMID: 34633041
This study aims to investigate utility of an ESM-tagged HDACi in inflammatory bowel disease (IBD). METHODS: CES1 expression was assessed in human blood, in vitro differentiated macrophage and dendritic cells and Crohn's disease (CD) colon mucosa by mass cytometry, quantita …
This study aims to investigate utility of an ESM-tagged HDACi in inflammatory bowel disease (IBD). METHODS: CES1 expression was asses …
Antibiotics in pediatric inflammatory bowel diseases: a systematic review.
Verburgt CM, Heutink WP, Kuilboer LIM, Dickmann JD, van Etten-Jamaludin FS, Benninga MA, de Jonge WJ, Van Limbergen JE, Tabbers MM. Verburgt CM, et al. Among authors: de jonge wj. Expert Rev Gastroenterol Hepatol. 2021 Aug;15(8):891-908. doi: 10.1080/17474124.2021.1940956. Epub 2021 Jul 6. Expert Rev Gastroenterol Hepatol. 2021. PMID: 34148466
Introduction: Current therapies in pediatric Inflammatory Bowel Diseases (IBD) target the immune system and often fail to sustain long-term remission. There is a high need for development of alternative treatment strategies such as antibiotics in pediatric IBD.Areas …
Introduction: Current therapies in pediatric Inflammatory Bowel Diseases (IBD) target the immune system and often fail to sustain lon …
Neuronal innervation of the intestinal crypt.
Ten Hove AS, Seppen J, de Jonge WJ. Ten Hove AS, et al. Among authors: de jonge wj. Am J Physiol Gastrointest Liver Physiol. 2021 Feb 1;320(2):G193-G205. doi: 10.1152/ajpgi.00239.2020. Epub 2020 Dec 9. Am J Physiol Gastrointest Liver Physiol. 2021. PMID: 33296267 Review.
Mucosal damage is a key feature of inflammatory bowel diseases (IBD) and healing of the mucosa is an endpoint of IBD treatment that is often difficult to achieve. ...
Mucosal damage is a key feature of inflammatory bowel diseases (IBD) and healing of the mucosa is an endpoint of IBD treatment …
Tyrosine Kinase 2 Signalling Drives Pathogenic T cells in Colitis.
De Vries LCS, Ghiboub M, van Hamersveld PHP, Welting O, Verseijden C, Bell MJ, Rioja I, Prinjha RK, Koelink PJ, Strobl B, Müller M, D'Haens GR, Wildenberg ME, De Jonge WJ. De Vries LCS, et al. Among authors: de jonge wj. J Crohns Colitis. 2021 Apr 6;15(4):617-630. doi: 10.1093/ecco-jcc/jjaa199. J Crohns Colitis. 2021. PMID: 33005945 Free PMC article.
BACKGROUND AND AIMS: Tyrosine kinase 2 [TYK2] is required for the signalling of key cytokines in the pathogenesis of inflammatory bowel disease [IBD]. We assessed the efficacy of a novel selective TYK2 inhibitor [TYK2i] in experimental colitis, using pharmacological and ge …
BACKGROUND AND AIMS: Tyrosine kinase 2 [TYK2] is required for the signalling of key cytokines in the pathogenesis of inflammatory bowel dise …
Characterization of gut-homing molecules in non-endstage livers of patients with primary sclerosing cholangitis and inflammatory bowel disease.
de Krijger M, Visseren T, Wildenberg ME, Hooijer GKJ, Verstegen MMA, van der Laan LJW, de Jonge WJ, Verheij J, Ponsioen CY. de Krijger M, et al. Among authors: de jonge wj. J Transl Autoimmun. 2020 Apr 9;3:100054. doi: 10.1016/j.jtauto.2020.100054. eCollection 2020. J Transl Autoimmun. 2020. PMID: 32743534 Free PMC article.
INTRODUCTION: The co-occurrence of inflammatory bowel disease (IBD) in up to 80% of patients with primary sclerosing cholangitis (PSC) suggests a relation between the gut and the liver in patients with both PSC and IBD. ...Only patients with concomitant IBD w …
INTRODUCTION: The co-occurrence of inflammatory bowel disease (IBD) in up to 80% of patients with primary sclerosing cholangitis (PSC …
Neuroimmune Interactions in the Gut and Their Significance for Intestinal Immunity.
Brinkman DJ, Ten Hove AS, Vervoordeldonk MJ, Luyer MD, de Jonge WJ. Brinkman DJ, et al. Among authors: de jonge wj. Cells. 2019 Jul 2;8(7):670. doi: 10.3390/cells8070670. Cells. 2019. PMID: 31269754 Free PMC article. Review.
Inflammatory bowel diseases (IBD) have a complex, multifactorial pathophysiology with an unmet need for effective treatment. ...
Inflammatory bowel diseases (IBD) have a complex, multifactorial pathophysiology with an unmet need for effective treatment. ...
Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis.
de Krijger M, Wildenberg ME, de Jonge WJ, Ponsioen CY. de Krijger M, et al. Among authors: de jonge wj. J Hepatol. 2019 Sep;71(3):603-615. doi: 10.1016/j.jhep.2019.05.006. Epub 2019 May 18. J Hepatol. 2019. PMID: 31108158 Review.
The pathophysiology of PSC is still unknown. The concurrence with inflammatory bowel disease (IBD) in about 70% of cases has led to the hypothesis that gut-homing lymphocytes aberrantly traffic to the liver, contributing to disease pathogenesis in patients with both PSC an …
The pathophysiology of PSC is still unknown. The concurrence with inflammatory bowel disease (IBD) in about 70% of cases has led to t …
β-Blocker use is associated with a higher relapse risk of inflammatory bowel disease: a Dutch retrospective case-control study.
Willemze RA, Bakker T, Pippias M, Ponsioen CY, de Jonge WJ. Willemze RA, et al. Among authors: de jonge wj. Eur J Gastroenterol Hepatol. 2018 Feb;30(2):161-166. doi: 10.1097/MEG.0000000000001016. Eur J Gastroenterol Hepatol. 2018. PMID: 29111997
We addressed whether an association exists between the use of beta-blockers and the course of IBD, defined by the risk of a disease relapse in patients with IBD. ...We calculated the number of relapses per 100 person-years and compared this between patients with …
We addressed whether an association exists between the use of beta-blockers and the course of IBD, defined by the risk of a disease r …
Inhibition of miR-142-5P ameliorates disease in mouse models of experimental colitis.
Duijvis NW, Moerland PD, Kunne C, Slaman MMW, van Dooren FH, Vogels EW, de Jonge WJ, Meijer SL, Fluiter K, Te Velde AA. Duijvis NW, et al. Among authors: de jonge wj. PLoS One. 2017 Oct 23;12(10):e0185097. doi: 10.1371/journal.pone.0185097. eCollection 2017. PLoS One. 2017. PMID: 29059189 Free PMC article.
They may be of importance in the pathogenesis of inflammatory bowel disease (IBD). The aim of this study was to determine the role of miRNAs by their specific blocking in the CD4+CB45RBhi T-cell transfer model of chronic experimental colitis. METHODS: Colitis caused by tra …
They may be of importance in the pathogenesis of inflammatory bowel disease (IBD). The aim of this study was to determine the role of …
17 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page